- Home
- BTAI vs TRIB Comparison
BTAI vs TRIB Comparison
Compare BTAI & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- TRIB
- Stock Information
- Founded
- BTAI 2017
- TRIB 1992
- Country
- BTAI United States
- TRIB Ireland
- Employees
- BTAI N/A
- TRIB N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BTAI Health Care
- TRIB Health Care
- Exchange
- BTAI Nasdaq
- TRIB Nasdaq
- Market Cap
- BTAI 10.7M
- TRIB 10.7M
- IPO Year
- BTAI 2018
- TRIB N/A
- Fundamental
- Price
- BTAI $1.46
- TRIB $0.84
- Analyst Decision
- BTAI Buy
- TRIB
- Analyst Count
- BTAI 5
- TRIB 0
- Target Price
- BTAI $42.60
- TRIB N/A
- AVG Volume (30 Days)
- BTAI 97.3K
- TRIB 73.0K
- Earning Date
- BTAI 05-12-2025
- TRIB 05-27-2025
- Dividend Yield
- BTAI N/A
- TRIB N/A
- EPS Growth
- BTAI N/A
- TRIB N/A
- EPS
- BTAI N/A
- TRIB N/A
- Revenue
- BTAI $1,852,000.00
- TRIB $59,126,000.00
- Revenue This Year
- BTAI $41.00
- TRIB $11.63
- Revenue Next Year
- BTAI $197.21
- TRIB $10.13
- P/E Ratio
- BTAI N/A
- TRIB N/A
- Revenue Growth
- BTAI 5.47
- TRIB N/A
- 52 Week Low
- BTAI $1.29
- TRIB $0.48
- 52 Week High
- BTAI $42.08
- TRIB $3.55
- Technical
- Relative Strength Index (RSI)
- BTAI 37.90
- TRIB 64.93
- Support Level
- BTAI $1.34
- TRIB $0.71
- Resistance Level
- BTAI $1.64
- TRIB $0.84
- Average True Range (ATR)
- BTAI 0.15
- TRIB 0.06
- MACD
- BTAI -0.01
- TRIB 0.00
- Stochastic Oscillator
- BTAI 16.56
- TRIB 74.24
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.